NCT04366245

Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection

Phase I / II Multicentre, Randomized and Controlled Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: Andalusian Network for Design and Translation of Advanced Therapies · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Phase I / II multicentre, randomized and controlled clinical trial to evaluate the efficacy of treatment with hyperimmune plasma obtained from convalescent antibodies of COVID-19 infection.

Conditions

• SARS-CoV 2

Interventions

Type	Name	Description
BIOLOGICAL	Hyperimmune plasma	PLASMA OF CONVALESCENT COVID-19
DRUG	Standard of care for SARS-CoV-2 infection	Standard of care for SARS-CoV-2 infection

Timeline

• Start date: 2020-04-23
• Primary completion: 2020-12-30
• Completion: 2020-12-30
• First posted: 2020-04-28
• Last updated: 2022-04-06

Locations

14 sites across 1 country: Spain